Can Zarxio (filgrastim) be used in patients with myelodysplastic syndrome (MDS) receiving an IPT regimen at 10 % of the usual dose?

Use of Zarxio (Filgrastim) in MDS Patients Receiving IPT at 10% Dosage

Zarxio should be used with extreme caution—if at all—in patients with MDS, as the safety of filgrastim products in myelodysplasia has not been established, and there are specific concerns about potential disease progression. 1

Critical Safety Concerns in MDS

The FDA label for Zarxio explicitly states that "the safety of filgrastim products in chronic myeloid leukemia (CML) and myelodysplasia has not been established." 1 This is a fundamental limitation that must guide clinical decision-making.

Risk of MDS/AML Transformation

In patients with severe chronic neutropenia (SCN) treated with filgrastim, cytogenetic abnormalities, transformation to MDS, and progression to AML have been documented. 1 While this risk appears confined primarily to congenital neutropenia patients, the concern about stimulating abnormal clones in existing MDS is significant. The FDA label warns that "the effect of filgrastim products on the development of abnormal cytogenetics and the effect of continued administration in patients with abnormal cytogenetics or MDS are unknown." 1

Potential Stimulation of Malignant Cells

Zarxio acts through the G-CSF receptor, which has been found on tumor cell lines, raising the possibility that it could act as a growth factor for malignant cells. 1 This theoretical concern is particularly relevant in MDS, where the bone marrow already contains dysplastic and potentially pre-leukemic clones.

Clinical Practice Guidelines on G-CSF in MDS

Limited Indications for G-CSF Use

Current guidelines restrict G-CSF use in MDS to very specific, short-term situations:

• For acute neutropenic fever with infection: G-CSF can be considered during severe infections in neutropenic MDS patients as an adjunct to antibiotics, but this should be short-term use only. 2 The 2014 ESMO guidelines note that "short-term use of G-CSF during severe infections could be useful in neutropenic patients, but this indication has not been validated." 2

• Not for prophylactic use: Prophylactic antibiotics and/or G-CSF are not recommended for chronic neutropenia in MDS, as they have not shown any impact on survival. 2, 3

Synergistic Use with Erythropoietin

The only established chronic use of G-CSF in MDS is at low doses (1-2 mcg/kg, not the standard 5 mcg/kg) in combination with erythropoietin for treating anemia in lower-risk MDS patients. 4 This represents approximately 20-40% of the standard dose and is used specifically for its erythroid synergistic effect, not for neutropenia management. The purpose is to help normalize neutrophil counts in initially neutropenic patients or double the count in non-neutropenic patients while primarily targeting anemia response. 4

Specific Concerns About "IPT 10% Dosage"

The reference to "IPT 10% dosage" is unclear, but if this refers to using 10% of standard filgrastim dosing:

• Standard G-CSF dosing is 5 mcg/kg/day 5
• 10% of this would be 0.5 mcg/kg/day, which is even lower than the 1-2 mcg/kg used for erythroid synergy with EPO 4
• At such low doses, the clinical benefit for neutropenia would be questionable, while the theoretical risks of stimulating dysplastic clones remain

Risk-Benefit Analysis Algorithm

If considering G-CSF in an MDS patient, evaluate:

1. Is there active, life-threatening infection with severe neutropenia (ANC <500)?

   • If YES: Short-term G-CSF may be justified as adjunctive therapy with antibiotics 2
   • If NO: Do not use G-CSF

2. Is the goal to enhance erythropoietin response for anemia in lower-risk MDS?

   • If YES: Consider low-dose G-CSF (1-2 mcg/kg) in combination with EPO, only if serum EPO >500 mU/mL 4
   • If NO: Do not use G-CSF

3. Is this for prophylactic neutropenia management?

   • Do not use G-CSF - no survival benefit demonstrated 2, 3

4. Does the patient have higher-risk MDS or increasing blast counts?

   • Absolutely avoid G-CSF - risk of stimulating leukemic progression 5

Common Pitfalls to Avoid

• Do not extrapolate chemotherapy-induced neutropenia guidelines to MDS: The 2000 ASCO guidelines explicitly state there is "no evidence that CSFs are of important benefit in patients with refractory or relapsed myeloid leukemia, and they should be used judiciously or not at all in such patients" due to concerns about stimulating leukemia growth. 5

• Do not use G-CSF for chronic prophylaxis in MDS: Unlike in chemotherapy patients, prolonged G-CSF use in MDS has not demonstrated survival benefit and carries theoretical risks. 2

• Monitor for disease progression: If G-CSF must be used short-term, closely monitor for signs of MDS/AML progression, including increasing blast counts and new cytogenetic abnormalities. 1

Bottom Line Recommendation

Given the lack of established safety in MDS, the absence of proven benefit for chronic use, and the theoretical risk of stimulating dysplastic clones, Zarxio should not be used routinely in MDS patients. The only justifiable uses are: (1) short-term adjunctive therapy during life-threatening neutropenic infections, or (2) low-dose combination with erythropoietin for anemia management in carefully selected lower-risk MDS patients. If a patient with MDS develops abnormal cytogenetics or signs of progression while on G-CSF, the risks and benefits of continuing should be carefully reconsidered, with strong consideration for discontinuation. 1